Erythropoietin 2000IU/0.5mL Injection

Erythropoietin 2000IU/0.5mL is an erythropoiesis-stimulating injection used for selected forms of anaemia, particularly those associated with chronic kidney disease. Some products also have defined uses in chemotherapy-associated anaemia. It is not a general energy supplement.
The injection is given intravenously or under the skin, with the schedule adjusted to haemoglobin response. A patient using it at home needs injection training. Store at 2-8 degrees C, protected from light; do not shake or freeze it.
Erythropoietin activates receptors on red-cell precursor cells in the bone marrow. This promotes development of red blood cells when adequate iron and other necessary nutrients are available.
Headache, raised blood pressure, joint discomfort and injection-site reactions can occur. Blood clots, stroke, heart attack, seizures and serious allergic reactions are important potential risks.
Uncontrolled hypertension must be corrected before treatment. Tell your doctor about previous clots, stroke, seizures and cancer treatment. Treatment uses the lowest dose needed to reduce transfusion requirements, not to push haemoglobin into the normal range.
Can reduce the need for red-cell transfusions when the cause of anaemia and response to treatment are appropriately assessed.
No. It stimulates red-cell production, whereas iron supplies material needed to make haemoglobin. Iron deficiency can limit the response to erythropoietin.
Red-cell production takes time. This medicine does not replace an urgent transfusion when rapid correction is necessary.
The dose needs adjustment if haemoglobin rises too quickly or exceeds the intended range. More rapid correction is not necessarily safer.
The team should assess iron status, inflammation, bleeding and other causes of poor response rather than repeatedly increasing the dose.
No. Eligibility depends on the chemotherapy plan, treatment intent and the particular product's indication. ESAs can worsen some cancer outcomes.
Report a marked blood-pressure rise or severe headache promptly. Chest pain, one-sided weakness or sudden breathlessness needs emergency assessment.
No. Products differ in formulation, concentration and injection device. The prescriber and pharmacist should manage any switch.
No. International units describe biological activity. The prescribed amount and the container presentation must both be confirmed before administration.
ESA: erythropoiesis-stimulating agent. Erythropoiesis: production of red blood cells. Haemoglobin: the oxygen-carrying protein in red cells. IU: international units of biological activity. Iron stores: the body's reserve of iron for blood-cell production.; AR: Erythropoietin 2000IU/0.5mL حقن; FR: Erythropoietin 2000IU/0.5mL injection; PT: Erythropoietin 2000IU/0.5mL injeção; ES: Erythropoietin 2000IU/0.5mL inyección; RU: Erythropoietin 2000IU/0.5mL инъекция; ID: Erythropoietin 2000IU/0.5mL injeksi; VI: Erythropoietin 2000IU/0.5mL thuốc tiêm; MS: Erythropoietin 2000IU/0.5mL suntikan; TL: Erythropoietin 2000IU/0.5mL iniksyon; ZH-SG: Erythropoietin 2000IU/0.5mL 注射剂
International B2B Enquiry
Send a structured B2B enquiry for Erythropoietin 2000IU/0.5mL Injection under Blood Care. Global Medicines Export helps international buyers review product information, pack details, quantity requirements, destination-market needs, quotation support and export documentation coordination from India.
Product name, required strength or pack, expected quantity, destination country, buyer type and preferred manufacturer if any.
Availability, quotation support, documentation expectations and shipment-ready order communication can be reviewed before confirmation.
Commercial invoice, packing information, manufacturer details, batch details and supporting documents where applicable and available.
Product availability, quotation, and documentation support are coordinated for international B2B enquiries.
Erythropoietin 2000IU/0.5mL Injection